Plug Power Inc (NASDAQ:PLUG) announced the completion of its previously announced underwritten public offering of 22,600,000 shares of its common stock at $5.50 per share. Morgan Stanley & Co. LLC and Barclays Capital Inc. acted as the book-running managers and Cowen and Company, LLC and FBR Capital Markets & Co. acted as co-managers for the offering. Net proceeds, after underwriting discounts and commissions and other estimated fees and expenses payable by Plug Power, were approximately $116,300,000. Plug Power intends to use the net proceeds of the offering for working capital and other general corporate purposes, which may include capital expenditures and potential acquisitions. Plug Power Inc (NASDAQ:PLUG) shares after opening at $4.67 moved to $4.98 on last trade day and at the end of the day closed at $4.69. Company price to sales ratio in past twelve months was calculated as 25.38 and price to cash ratio as 135.04. Plug Power Inc (NASDAQ:PLUG) showed a negative weekly performance of -21.96%.
InvenSense, Inc. (NYSE:INVN), a leading provider of Motion Tracking(TM) sensor system on chip (SoC) and Sound devices, announced its fourth quarter and fiscal year 2014 results. Net revenue for the fourth fiscal quarter of 2014 was $59.0 million, up from $55.2 million for the fourth fiscal quarter of 2013. Net revenue for the fiscal year 2014 was $252.5 million, up from $208.6 million for the fiscal year 2013. InvenSense Inc (NYSE:INVN) shares fell -4.37% in last trading session and ended the day on $20.59. INVN return on equity ratio is recorded as 9.00% and its return on assets is 7.20%. InvenSense Inc (NYSE:INVN) yearly performance is 125.77%.
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) announced that the U.S. District Court for the District of Delaware has ruled in favor of Avanir in the company’s patent infringement lawsuit against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc. in conjunction with their Abbreviated New Drug Applications (‘ANDAs’) for generic versions of NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules for the treatment of pseudobulbar affect. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) shares moved down -6.63% in last trading session and was closed at $4.65, while trading in range of $ 4.45 – 5.06. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) year to date (YTD) performance is 38.39%.
Vonage Holdings Corp. (NYSE:VG) announced its earnings results on Thursday. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03, ARN reports. The company had revenue of $221.00 million for the quarter, compared to the consensus estimate of $219.60 million. During the same quarter in the previous year, the company posted $0.10 earnings per share. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. Vonage Holdings Corp. (NYSE:VG) weekly performance is 11.83%. On last trading day company shares ended up $4.35. Vonage Holdings Corp.(NYSE:VG) distance from 50-day simple moving average (SMA50) is 2.06%. Analysts mean target price for the company is $6.38.